Acyclovir Articles
WELLCOME INTERIMS DRIVEN BY ZOVIRAX
29 March 1993
NEW DATA ON ZIDOVUDINE, ACICLOVIR COTHERAPY
29 March 1993
EIRE POM TO P SWITCH
15 March 1993
ACICLOVIR SHOULD GO OTC, SAYS UK MCA
1 February 1993
GLOBAL DRUG MARKET: 30 YEARS OF GROWTH
4 January 1993
ZOVIRAX OF LIMITED USE IN CHICKENPOX?
4 January 1993
WELLCOME'S US "TIDAL WAVE" REVERSING?
21 December 1992
WELLCOME STARTS ZOVIRAX PROGRAM
14 December 1992
WELLCOME PRETAX PROFITS RISE 25%
2 November 1992
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
FIRST EC LAUNCH OF ZOVIRAX
6 July 1992
WELLCOME LOOKING TO OTC ZOVIRAX
29 June 1992
COPROMOTION DEAL FOR ZOVIRAX IN USA
8 June 1992
ASTRA TO FUND CMV TREATMENT STUDY
25 May 1992
EUROPEAN MARKET FOR SELF-MEDICATION
18 May 1992
NEW ZOVIRAX DATA FOR CHICKENPOX
4 May 1992
ZOVIRAX AND SHINGLES
13 April 1992
MORE EXPANSION AT CHILE'S LABS SAVAL
23 March 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
FURTHER WELLCOME SHARE SELL-OFF
9 March 1992
ZOVIRAX ENDORSED FOR CHICKENPOX
9 March 1992
STOCK MARKET COMMENTARY: EUROPE
9 March 1992
"EXCELLENT START" TO 1992 AT WELLCOME
27 January 1992
DRUG FIRMS ARE STOCK MARKET DARLINGS
13 January 1992
STOCK MARKET COMMENTARY: EUROPE
6 January 1992
ZOVIRAX/RETROVIR COMBO FOR AIDS?
6 January 1992
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
